SCHEMBL23927459

SCHEMBL23927459

CCOC(=O)c1nnc(Cc2cccc(C(F)(F)F)c2F)[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.41
GRIA2 P42262 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
P2RX7 Q99572 2/20 0.39
CACNA1C Q13936 2/20 0.39
AKR1B1 P15121 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
USP2 O75604 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CD38 P28907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15964605 0.85 NPC1 (0.43) KDM4EALDH1A1L3MBTL1HSD17B10CYP1A2
SCHEMBL23927449 0.83 ALOX5 (0.40) P2RX7MRGPRX4ALDH1A1TP53CYP1A2
SCHEMBL30091692 0.83 ALOX5 (0.40) P2RX7MRGPRX4ALDH1A1TP53CYP1A2
SCHEMBL30091557 0.83 CD38 (0.41) GRIA2GRIN1GRIN2AP2RX7AKR1B1
SCHEMBL17324405 0.80 KMT2A (0.50) KDM4EPOLBALDH1A1L3MBTL1
SCHEMBL23927507 0.80 HPGD (0.40) KDM4EP2RX7ALDH1A1L3MBTL1TP53
SCHEMBL23927444 0.78 P2RX7 (0.42) KDM4EPOLBP2RX7CACNA1CALDH1A1
SCHEMBL23189116 0.77 TSHR (0.44) KDM4EALDH1A1RECQLHSD17B10CYP1A2
SCHEMBL23927496 0.77 KDM4E (0.40) KDM4EPOLBMRGPRX4ALDH1A1L3MBTL1
SCHEMBL17324355 0.76 PTGES (0.48) KDM4EALDH1A1L3MBTL1HSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 KDM4E 1934/4885POLB 4427/4885GRIA2 837/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 KDM4E 1934/4885POLB 4427/4885GRIA2 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.